

《 食道癌抗癌藥物治療指引 》

Preoperative Chemoradiation Therapy of Esophageal Cancer Preferred Regimens

Paclitaxel + Carboplatin

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Paclitaxel	50	1	QW	5	1
Carboplatin	AUC 2	1	QW	5	

Cisplatin + Fluoropyrimidine

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Cisplatin	75	1	Q4W	2(RT) + 2	2
5-FU	1000*	1-4	Q4W	2(RT) + 2	

* Continuous infusion for 24 hours

藥品名 *	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Cisplatin	15	1-5	Q3W	2	5
5-FU	800*	1-5	Q3W	2	

* Continuous infusion for 24 hours

藥品名 *	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Cisplatin	30	1	QW	5	43
Capecitabine	800 PO BID	1-5	QW	5	

Oxaliplatin + Fluoropyrimidine

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Oxaliplatin	85	1	Q2W	3(RT) + 3	2
Leucovorin	400	1	Q2W	3(RT) + 3	
5-FU	400	1	Q2W	3(RT) + 3	
5-FU	800*	1-2	Q2W	3(RT) + 3	

* Continuous infusion for 24 hours

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Oxaliplatin	85	1, 15, 29		For 3 doses	42
Capecitabine	625 PO BID	1-5	QW	5	

Other Regimens

Cisplatin + Fluorouracil

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Cisplatin	100	1, 29	Q35D	1	4
5-Fu	1000	1-4, 29-32	Q35D	1	

Irinotecan + Cisplatin

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Irinotecan	65	1, 8, 22, 29		1	6
Cisplatin	30	1, 8, 22, 29		1	

Paclitaxel + Fluoropyrimidine

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Paclitaxel	45	1	QW	5	7
5-FU	300*	1-5	QW	5	

* Continuous infusion for 24 hours

Perioperative Chemotherapy (Include EGJ)

Preferred Regimens

ECF modications

藥品名 *	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Epirubicin	50	1	Q3W	6*	9
Cisplatin	60	1	Q3W	6*	
Capecitabine	625 PO BID	1-21	Q3W	6*	

*3(pre-op) + 3(post-op)

藥品名 *	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Epirubicin	50	1	Q3W	6*	9
Oxaliplatin	130	1	Q3W	6*	
Capecitabine	625 PO BID	1-21	Q3W	6*	

*3(pre-op) + 3(post-op)

Oxaliplatin + Fluoropyrimidine

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Oxaliplatin	85	1	Q2W	6 [#]	22
Leucovorin	400	1	Q2W	6 [#]	
5-FU	400	1	Q2W	6 [#]	
5-FU	1200*	1-2	Q2W	6 [#]	

* Continuous infusion for 24 hours [#]3 (pre-op) + 3 (post-op)

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Oxaliplatin	85	1	Q2W	6 [#]	19
Leucovorin	200	1	Q2W	6 [#]	
5-FU	2600*	1	Q2W	6 [#]	

* Continuous infusion for 24 hours [#]3 (pre-op) + 3 (post-op)

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Oxaliplatin	130	1	Q3W	6 [#]	23
Capecitabine	1000 PO BID	1-14	Q3W	6 [#]	

[#]3 (pre-op) + 3 (post-op)

Oxaliplatin + Fluoropyrimidine

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Docetaxel	50	1	Q2W	8 [#]	8
Oxaliplatin	85	1	Q2W	8 [#]	
Leucovorin	200	1	Q2W	8 [#]	
5-FU	2600*	1	Q2W	8 [#]	

* Continuous infusion for 24 hours [#]4 (pre-op) + 4 (post-op)

Other Regimens

Cisplatin + Fluorouracil

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Cisplatin	100	1	Q4W	6 [#]	9
5-Fu	800*	1-5	Q4W	6 [#]	

* Continuous infusion for 24 hours [#]2-3 (pre-op) + 3-4 (post-op)

Preoperative Chemotherapy

(Only for adenocarcinoma of the thoracic esophagus or EGJ)

Cisplatin + Fluorouracil

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Cisplatin	80	1	Q3W	2 [#]	10
5-Fu	1000*	1-4	Q3W	2 [#]	

* Continuous infusion for 24 hours [#]2(pre-op)

Definitive Chemoradiation (Non-Surgical)

Preferred Regimens

Oxaliplatin + Fluoropyrimidine

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Oxaliplatin	85	1	Q2W	6 [#]	5
Leucovorin	400	1	Q2W	6 [#]	
5-FU	400	1	Q2W	6 [#]	
5-FU	800*	1-2	Q2W	6 [#]	

* Continuous infusion for 24 hours [#]3 (RT) + 3 (post-RT)

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Oxaliplatin	85	1, 15, 29		For 3 doses	42
Capecitabine	625 PO BID	1-5	QW	5	

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Oxaliplatin	85	1, 15, 29			3
5-FU	180	1-33			

Paclitaxel + Carboplatin

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Paclitaxel	50	1	QW	5	1
Carboplatin	AUC 2	1	QW	5	

Other Regimens

Cisplatin + Fluoropyrimidine

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Cisplatin	75	1	Q4W	2~4#	11
5-FU	1000*	1-4	Q4W	2~4#	

* Continuous infusion for 24 hours #2 (RT) + 2

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Cisplatin	30	1	QW	5	41
Capecitabine	800 PO BID	1-5	QW	5	

Taxane + Cisplatin

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Paclitaxel	60	1, 8, 15, 22		1	12
Cisplatin	75	1		1	

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Docetaxel	60	1, 22		1	13
Cisplatin	80	1, 22		1	

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Docetaxel	30	1	QW	5	14
Cisplatin	30	1	QW	5	

Irinotecan + Cisplatin

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Irinotecan	65	1, 8, 22, 29		1	6
Cisplatin	30	1, 8, 22, 29		1	

Paclitaxel + Fluoropyrimidine

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Paclitaxel	45-50	1	QW	5	7
5-FU	300*	1-5	QW	5	

* Continuous infusion for 24 hours

Postoperative Chemoradiation (Including EGJ)

5-FU (bolus) + Leucovorin

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Lecucovorin	20	1-5	Q4W	1 st , 3 rd , 4 th #	15, 44
5-FU	425	1-5	Q4W	1 st , 3 rd , 4 th #	
Lecucovorin	20	1-4, 31-33	Q5W	2 nd (with RT)	
5-FU	400	1-4, 31-33	Q5W	2 nd (with RT)	

#Cycle 1st (pre-RT), and cycle 3rd, 4th (post-RT)

5-FU + Leucovorin modifications

1 cycle before + 2 cycle after chemoradiation

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Capecitabine	1000 PO BID	1-14	Q4W	1 + 2	45

2 cycle before + 4 cycle after chemoradiation

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Leucovorin	400	1	Q2W	2 + 4	58
5-FU	400	1	Q2W	2 + 4	
5-FU	1200*	1-2	Q2W	2 + 4	

*Continuous infusion for 24 hours

With radiation

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
5-FU	200*	1-5 or 1-7	QW	5 with RT	46

*Continuous infusion for 24 hours

藥品名 *	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Capecitabine	825 PO BID	1-5 or 1-7	QW	5 with RT	47

Postoperative Chemotherapy

Preferred Regimens

Nivolumab only after preoperative chemoradiation with R0 resection and residual disease

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Nivolumab	240 mg	1	Q2W	8	49
Followed by					
Nivolumab	480 mg	1	Q4W	For max 1 year	

Other Recommended Regimens

Oxaliplatin + Capecitabine

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Oxaliplatin	130	1	Q3W		16
Capecitabine	1000 PO BID	1-14	Q3W		

Oxaliplatin + Fluorouracil

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Oxaliplatin	85	1	Q2W		22
Leucovorin	400	1	Q2W		
5-FU	400	1	Q2W		
5-FU	1200*	1-2	Q2W		

* Continuous infusion for 24 hours #3 (RT) + 3 (post-RT)

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Oxaliplatin	85	1	Q2W		19
Leucovorin	200	1	Q2W		
5-FU	2600*	1	Q2W		

* Continuous infusion for 24 hours #3 (RT) + 3 (post-RT)

Neoadjuvant or Perioperative Immunotherapy

Nivolumab and Ipilimumab followed by Nivolumab (MSI-H/dMMR)

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Nivolumab	240 mg	1	Q2W	Pre-OP X 6	54
Ipilimumab	1 mg/kg	1	Q6W	Pre-OP X 2	
Followed by surgery					
Nivolumab	480 mg	1	Q4W	Pre-OP X 9	

Pembrolizumab (MSI-H/dMMR)

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	1	Q3W	Pre-OP X 2	55, 56
Followed by surgery					
Pembrolizumab	200 mg	1	Q3W	Pre-OP X 5	

Tremelimumab + Durvalumab (MSI-H/dMMR) (for neoadjuvant therapy only)

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Tremelimumab	300 mg	1	Q12W	Pre-OP X 1	57
Durvalumab	1500 mg	1	Q4W	Pre-OP X 3	

Systemic therapy for metastatic or locally advanced cancer (where local therapy is not indicated)

First-line Therapy**Trastuzumab (with chemotherapy)**

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Trastuzumab	8 → 6 mg/kg	1	Q3W		17, 53

Trastuzumab (with chemotherapy)

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Trastuzumab	6 → 4 mg/kg	1	Q2W		17

Preferred Regimens

± Nivolumab + Oxaliplatin + Capecitabine

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
± Nivolumab	360 mg	1	Q3W		51
Oxaliplatin	130	1	Q3W		23
Capecitabine	1000 PO BID	1-14	Q3W		

For adenocarcinoma (PD-L1 CPS: 1-4, category 2B; ≥ 5, category 1) or Squamous cell carcinoma.

*2023 NCCN & 團隊共識

± Nivolumab + Oxaliplatin + 5Fu

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
± Nivolumab	240 mg	1	Q2W		50
Oxaliplatin	85	1	Q2W		22
Leucovorin	400	1	Q2W		
5-FU	400	1	Q2W		
5-FU	1200*	1-2	Q2W		

For adenocarcinoma (PD-L1 CPS: 1-4, category 2B; ≥ 5, category 1) or Squamous cell carcinoma.

* Continuous infusion for 24 hours

Nivolumab + 5FU + Cisplatin

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Nivolumab	360 mg	1	Q3W	Max 2 years	50
Cisplatin	80	1	Q3W	Max 2 years	54
Capecitabine	850~1000* PO BID	1-14	Q3W	Max 2 years	

*2023 NCCN & 團隊共識

Pembrolizumab + Oxaliplatin + Capecitabine

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	1	Q3W	Up to 2 years	51
Oxaliplatin	130	1	Q3W	6	
Capecitabine	1000 PO BID	1-14	Q3W	6	

*2023 NCCN & 團隊共識

Pembrolizumab + Oxaliplatin + 5Fu

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	1	Q2W	Up to 2 years	51
Oxaliplatin	85	1	Q2W	9	
Leucovorin	400	1	Q2W	9	
5-FU	400	1	Q2W	9	
5-FU	1200*	1-2	Q2W	9	

* Continuous infusion for 24 hours

Pembrolizumab + Cisplatin + 5Fu

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	1	Q3W	Up to 2 years	51
Cisplatin	80	1	Q3W	6	
5-Fu	800*	1-5	Q3W	6	

* Continuous infusion for 24 hours

Pembrolizumab + Cisplatin + Capecitabine

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	1	Q3W	Up to 2 years	51
Cisplatin	80	1	Q3W	6	
Capecitabine	1000 PO BID	1-14	Q3W	6	

*2023 NCCN & 團隊共識

Fluoropyrimidine + Cisplatin

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Cisplatin	100	1	Q4W		18
5-FU	1000*	1-4	Q4W		

* Continuous infusion for 24 hours

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Cisplatin	50	1	Q2W		19, 20
Leucovorin	200	1	Q2W		
5-FU	2000*	1	Q2W		

* Continuous infusion for 24 hours

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Cisplatin	80	1	Q3W		21
Capecitabine	1000 PO BID	1-4	Q3W		

*2023 NCCN & 團隊共識

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Nivolumab	3 mg/kg	1	Q3W	Max 2 years	53
Ipilimumab	1 mg/kg	1	Q6W		

Fluoropyrimidine + Oxaliplatin

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Oxaliplatin	85	1	Q2W		19
Leucovorin	200	1	Q2W		
5-FU	2600*	1	Q2W		

* Continuous infusion for 24 hours

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Oxaliplatin	85	1	Q3W		47
Capecitabine	625 PO BID	1-14	Q3W		

MSI-H/dMMR tumors (independent of PD-L1 status)

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	1	Q3W		55

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Pembrolizumab	400 mg	1	Q6W		56

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Nivolumab	1 mg/kg	1	Q3W	4	57
Ipilimumab	3 mg/kg	1	Q3W	4	
Followed by					
Nivolumab	240 mg	1	Q2W	Max 2 years	

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Nivolumab	240 mg	1	Q3W	4	57
Ipilimumab	1 mg/kg	1	Q3W	4	
Followed by					
Nivolumab	240 mg (480 mg)	1	Q2W (Q4W)	Max 2 years	

Other Regimens

Paclitaxel + Cisplatin/Carboplatin

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Paclitaxel	200	1	Q3W		24
Cisplatin	75	2	Q3W		

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Paclitaxel	90	1	Q2W		25
Cisplatin	50	1	Q2W		

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Paclitaxel	200	1	Q3W		26
Carboplatin	AUC 5	1	Q3W		

Docetaxel + Cisplatin

藥品名*	劑量 mg/m ² *	給藥日	頻率	週期	參考文獻
Docetaxel	75-85	1	Q3W		27, 28
Cisplatin	70-75	1	Q3W		

Fluoropyrimidine

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Leucovorin	400	1	Q2W		20
5-FU	400	1	Q2W		
5-FU	1200*	1-2	Q2W		

* Continuous infusion for 24 hours

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
5-FU	800*	1-5	Q4W		29

* Continuous infusion for 24 hours

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Capecitabine	1250 PO BID	1-14	Q3W		30

Taxane

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Docetaxel	100	1	Q3W		31, 32

藥品名 *	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Paclitaxel	250	1	Q3W		33

藥品名 *	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Paclitaxel	80	1	QW		34

Irinotecan + 5-FU (only for adenocarcinoma)

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Irinotecan	180	1	Q2W		35
Leucovorin	400	1	Q2W		
5-FU	400	1	Q2W		
5-FU	1200*	1-2	Q2W		

* Continuous infusion for 24 hours

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Irinotecan	80	1	QW	6 + 2(off)#	48
Leucovorin	500	1	QW	6 + 2(off)#	
5-FU	2000*	1	QW	6 + 2(off)#	

* Continuous infusion for 24 hours #6 weeks treatment, followed by 2 weeks off

ECF

藥品名*	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Epirubicin	50	1	Q3W		38
Cisplatin	60	1	Q3W		
5-Fu	200*	1-21	Q3W		

* Continuous infusion for 24 hours

ECF modifications

藥品名*	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Epirubicin	50	1	Q3W		39, 40
Oxaliplatin	130	1	Q3W		
5-Fu	200*	1-21	Q3W		

* Continuous infusion for 24 hours

藥品名*	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Epirubicin	50	1	Q3W		39, 40
Cisplatin	60	1	Q3W		
Capecitabine	625 PO BID	1-21	Q3W		

藥品名*	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Epirubicin	50	1	Q3W		38
Oxaliplatin	130	1	Q3W		
Capecitabine	625 PO BID	1-21	Q3W		

DCF modifications

藥品名*	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Docetaxel	40	1	Q2W		36
Leucovorin	400	1	Q2W		
5-FU	400	1	Q2W		
5-FU	1000*	1-2	Q2W		
Cisplatin	40	3	Q2W		

* Continuous infusion for 24 hours

藥品名*	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Docetaxel	50	1	Q2W		37
Oxaliplatin	85	1	Q2W		
5-FU	1200*	1-2	Q2W		

* Continuous infusion for 24 hours

★三院有個別版本

參考文獻

1. Van Hagen P, Hulshof MC, van Lanschot, J.J, et al. Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer. *N Engl J Med* 2012;366:2074-2084.
2. Conroy T, Galais MP, Raoul JL, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ ACCORD17): final results of a randomised, phase 2/3 trial. *Lancet Oncol* 2014;15:305-314.
3. Khushalani NI, Leichman CG, Proulx G, et al. Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. *J Clin Oncol* 2002;20:2844-2850.
4. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. *J Clin Oncol* 2008;26:1086-1092.
5. Bedenne L, Michel P, Bouche O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. *J Clin Oncol* 2007; 25:1160-1168.
6. Sharma R, Yang GY, Nava HR, et al. A single institution experience with neoadjuvant chemoradiation (CRT) with irinotecan (I) and cisplatin (C) in locally advanced esophageal carcinoma (LAEC) [abstract]. *J Clin Oncol* 2009;27 (Suppl 15):Abstract e15619.
7. Ajani JA, Winter K, Okawara GS, et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. *J Clin Oncol* 2006;24:3953-3958.
8. Al-Batran SE, Hofheinz RD, Pauligk C, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. *Lancet Oncol* 2016;17:1697-1708.
9. Ychou M, Boige V, Pignon J-P, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. *J Clin Oncol* 2011;29:1715-1721.

10. Alderson D, Langley RE, Nankivell MG, et al. Neoadjuvant chemotherapy for resectable oesophageal and junctional adenocarcinoma: Results from the UK Medical Research Council randomised OEO5 trial (ISRCTN 01852072) [abstract]. *J Clin Oncol* 2015;33 (15_suppl):Abstract 4002.
11. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: highdose versus standard-dose radiation therapy. *J Clin Oncol* 2002;20:1167-1174.
12. Urba SG, Orringer MB, Ianettonni M, et al. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophagealcarcinoma. *Cancer* 003;98:2177-2183.
13. Li QQ, Liu MZ, Hu YH, et al. Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esophageal carcinoma. *Dis Esophagus* 2010;23:253-259.
14. Day FL, Leong T, Ngan S, et al. Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer. *Br J Cancer* 2011;104:265-271.
15. Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. *J Clin Oncol* 2012;30:2327-2333
16. Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomized phase 3 trial. *Lancet Oncol* 2014; 15:1389-1396.
17. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet* 2010;376:687-697.
18. Lorenzen S, Schuster T, Porschen R, et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. *Ann Oncol* 2009;20:1667-1673.
19. Al-Batran S-E, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. *J*

- Clin Oncol 2008;26:1435-1442.
20. Bouche O, Raoul JL, Bonnetain F, et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803. *J Clin Oncol* 2004;22:4319-4328.
 21. Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. *Ann Oncol* 2009;20:666-673.
 22. Enzinger PC, Burtness B, Hollis D, et al. CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer [abstract]. *J Clin Oncol* 2010;28 (Suppl 15):Abstract 4006.
 23. Kim GM, Jeung HC, Rha SY, et al. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. *Eur J Cancer* 2012;48:518-526.
 24. Ilson DH, Forastiere A, Arquette M, et al. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. *Cancer J* 2000;6:316-323.
 25. Petrasch S, Welt A, Reinacher A, et al. Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. *Br J Cancer* 1998;78:511-514.
 26. Gadgeel SM, Shields AF, Heilbrun LK, et al. Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer. *Am J Clin Oncol* 2003;26:37-41.
 27. Ajani JA, Fodor MB, Tjulandin SA, et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. *J Clin Oncol* 2005;23:5660-5667.
 28. Kim JY, Do YR, Park KU, et al. A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer. *Cancer Chemother Pharmacol* 2010;66:31-36.
 29. Ohtsu A, Shimada Y, Shirao K, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). *J Clin Oncol* 2003;21:54-59.

30. Hong YS, Song SY, Lee SI, et al. A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. *Ann Oncol* 2004;15:1344-1347.
31. Albertsson M, Johansson B, Friesland S, et al. Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer. *Med Oncol* 2007;24:407-412.
32. Ford HE, Marshall A, Bridgewater JA, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. *Lancet Oncol* 2014;15:78-86.
33. Ajani JA, Ilson DH, Daugherty K, et al. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. *J Natl Cancer Inst* 1994;86:1086-1091.
34. Ilson DH, Wadleigh RG, Leichman LP, Kelsen DP. Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. *Ann Oncol* 2007;18:898-902.
35. Guimbaud R, Louvet C, Ries P, et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: A French Intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en ncologie) Study. *J Clin Oncol* 2014;32:3520-3526.
36. Shah MA, Janjigian YY, Stoller R, et al. Randomized multicenter phase II study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: a study of the US Gastric Cancer Consortium. *J Clin Oncol* 2015;33:3874-3879.
37. Shankaran V, Mulcahy MF, Hochster HS, et al. Docetaxel, oxaliplatin, and 5-fluorouracil for the treatment of metastatic or unresectable gastric or gastroesophageal junction (GEJ) adenocarcinomas: Preliminary results of a phase II study. *Gastrointestinal Cancers Symposium 2009:Abstract 47*.
38. Elkerim YM, Elsaid A, AL-Batran S, Pauligk C. Final results of a phase II trial of docetaxel-carboplatin-FU in locally advanced gastric carcinoma [abstract]. Presented at the Gastrointestinal Cancers Symposium 2008. Abstract 38.
39. Ross P, Nicolson M, Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. *J*

- Clin Oncol 2002;20:1996-2004.
40. Sumpter K, Harper-Wynne C, Cunningham D, et al. Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer 2005;92:1976-1983.
 41. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36-46.
 42. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017;357:409-413.
 43. Javle MM, Yang G, Nwogu CE, et al. Capecitabine, oxaliplatin and radiotherapy: a phase IB neoadjuvant study for esophageal cancer with gene expression analysis. Cancer Invest 2009;27:193-200.
 44. Lee SS, Kim SB, Park SI, et al. Capecitabine and cisplatin chemotherapy (XP) alone or sequentially combined chemoradiotherapy containing XP regimen in patients with three different settings of stage IV esophageal cancer. Jpn J Clin Oncol 2007;37:829-835.
 45. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-730.
 46. Jansen EP, Boot H, Saunders MP, et al. A phase I-II study of postoperative capecitabine-based chemoradiotherapy in gastric cancer. Int J Radiat Oncol Biol Phys 2007;69:1424-1428.
 47. Leong T, Joon DL, Willis D, et al. Adjuvant chemoradiation for gastric cancer using epirubicin, cisplatin, and 5-fluorouracil before and after three-dimensional conformal radiotherapy with concurrent infusional 5-fluorouracil: a multicenter study of the trans-tasman radiation oncology group. Int J Radiat Oncol Biol Phys 2011;79:690-695.
 48. Lee HS, Choi Y, Hur WJ, et al. Pilot study of postoperative adjuvant chemoradiation for advanced gastric cancer: adjuvant 5-FU/cisplatin and chemoradiation with capecitabine. World J Gastroenterol 2006;12:603-607.
 49. Wolff K, Wein A, Reulbach U, et al. Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial. Anticancer Drugs 2009;20:165-173.
 50. Kelly R, Ajani J, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer

- following neoadjuvant chemoradiation therapy: first results of the CheckMate 577 study. [abstract]. Presented at the Oral Presentation presented at the ESMO 2020 Annual Meeting; September 19-21, 2020; Virtual Meeting.
51. Moehler M, Shitara K, Garrido M, et al. Nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/ esophageal adenocarcinoma: first results of the CheckMate 649 study. [abstract]. Presented at the Oral Presentation presented at the ESMO 2020 Annual Meeting; September 19-21, 2020; Virtual Meeting
 52. Kato K., Sun JM., M. S, et al. Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: the phase 3 KEYNOTE-590 study. [abstract]. Presented at the Presented at ESMO Annual Meeting; September 19-21, 2020; Virtual Meeting.
 53. Chung HC, et al First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811. *Future Oncol* 2021;17:491-501.
 54. Doki Y, Ajani JA, Kato K, et al. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. *N Engl J Med.* 2022 Feb 3;386(5):449-462.
 55. Kojima T, Shah MA, Muro K, et al. KEYNOTE-181 Investigators. Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. *J Clin Oncol.* 2020 Dec 10;38(35):4138-4148. doi: 10.1200/JCO.20.01888. Epub 2020 Oct 7. PMID: 33026938.
 56. Lala M, Li TR, de Alwis DP, et al. A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation. *Eur J Cancer.* 2020 May;131:68-75. doi: 10.1016/j.ejca.2020.02.016. Epub 2020 Apr 15. Erratum in: *Eur J Cancer.* 2021 Feb;144:400. PMID: 32305010.
 57. Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. *Lancet.* 2021 Jul 3;398(10294):27-40. doi: 10.1016/S0140-6736(21)00797-2. Epub 2021 Jun 5. PMID: 34102137; PMCID: PMC8436782.
 58. NCCN Guideline v 3.2023. Esophageal and Esophagogastric Junction Cancers. ESOPH-F 11 of 22.